Rob Grubka
Analyst · JPMorgan. Please proceed with your question.
Yes, sure. Thanks. Yes, Jimmy, as we looked at Stop Loss, even sort of, call it, pre-COVID as we were finishing up 2019, we felt good about what we were seeing in the underlying data and the claims activity. And we've sort of been on this trend over, frankly, a number of years of just working on the right balance of growth, right balance with pricing and renewal activity and trying to thread the needle there in a good way. I think you've seen that really come home versus some sort of secondary or primary impact from COVID and reluctance to go to a hospital. When you think about our business, as a reminder, we talk about middle and upmarket focus. You can think about deductibles at an individual level between 200,000 or 300,000 sort of is the sort of the middle of the curve, so to speak, of where most of our exposure would sit. And so look, those aren't oh boy, I've got cancer. I don't think I'm going to the hospital sort of moments. It's they've got something serious going on. If they're in treatment on a program, whatever the diagnosis may be, those are generally not going to be voluntary sorts of decisions that people just sort of opt out of and I'll go later moments. So look, this is a real combination of, I think, just discipline around the business, a continuing of the trend that we've seen and the results moving in the direction that we want them to. Now as we look, as you play this forward, can there be some knock-on impacts or delay things on the edges? Again, sure on the edges. But as Mike talked about sort of the range estimate around second quarter as well as the longer-term view of that broader range of COVID impact, we don't really anticipate a lot of noise to any noise within Stop Loss. Again, just given where we fit in the market, the types of cases we sell, how we position our product, I think it's going to be very modest to not at all.